Compounds, compositions and methods for treatment of arthritis
WO2012012890A1
Compounds, compositions and methods for treatment of arthritis
WO2011137511A1
Compounds, compositions and methods for treatment of central nervous system injuries
AU2009301603A1
Use of scyllo-inositols for the treatment of macular degeneration-related disorders
EP2656839A1
Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases
WO2008106775A1
Combination treatment for diabetes using an egf receptor ligand and a gastrin compound
WO2008071010A1
Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
WO2007134449A1
Screening methods for amyloid beta modulators
CN101505741A
A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
NZ571181A
A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
WO2007095737A1
Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
CA2579188A1
Treatment of amyloid-related diseases
WO2007062531A1
Combination treatments with gastrin agonists for diabetes and related diseases
WO2007041855A1
Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
CN101365476A
Combined use of dpp iv inhibitors and gastrin compounds
EP1765873A1
Methods and compositions using cd3 agonists
AU2005207870A1
The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels
CN1938334A
Combined use of a GLP-1 agonist and gastrin compounds
KR20060017617A
Compositions comprising gastrin compounds and their use in diabetes
CA2527186A1
Compositions comprising gastrin compounds and their use in diabetes
